Drugs / LY4050784
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06561685 | Sep 2024 → Oct 2027 expected | metastatic neoplasm, non-small cell lung carcinoma | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY4050784 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06561685 ↗ |
| Action | Inhibit | “a Selective SMARCA2/BRM Inhibitor” NCT06561685 ↗ |
| Route | Oral | “Oral” NCT06561685 ↗ |
| Target | SMARCA2 | “a Selective SMARCA2/BRM Inhibitor” NCT06561685 ↗ |